CN100581541C - 总状花升麻提取物在生产用于抑制黄体生成素活性的雌激素型器官选择性药物中的用途 - Google Patents

总状花升麻提取物在生产用于抑制黄体生成素活性的雌激素型器官选择性药物中的用途 Download PDF

Info

Publication number
CN100581541C
CN100581541C CN03145494A CN03145494A CN100581541C CN 100581541 C CN100581541 C CN 100581541C CN 03145494 A CN03145494 A CN 03145494A CN 03145494 A CN03145494 A CN 03145494A CN 100581541 C CN100581541 C CN 100581541C
Authority
CN
China
Prior art keywords
estrogen
extract
raceme
estradiol
shegan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN03145494A
Other languages
English (en)
Chinese (zh)
Other versions
CN1509712A (zh
Inventor
W·武特克
H·哈里
V·克里斯托夫
B·施彭格勒
M·波珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRONORICA ARZNEIMITTEL GmbH
Original Assignee
BRONORICA ARZNEIMITTEL GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7861630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100581541(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BRONORICA ARZNEIMITTEL GmbH filed Critical BRONORICA ARZNEIMITTEL GmbH
Publication of CN1509712A publication Critical patent/CN1509712A/zh
Application granted granted Critical
Publication of CN100581541C publication Critical patent/CN100581541C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN03145494A 1998-03-19 1999-03-19 总状花升麻提取物在生产用于抑制黄体生成素活性的雌激素型器官选择性药物中的用途 Expired - Fee Related CN100581541C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19812204A DE19812204A1 (de) 1998-03-19 1998-03-19 Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung
DE19812204.7 1998-03-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB998041238A Division CN100444867C (zh) 1998-03-19 1999-03-19 含有鸢尾黄素的射干提取物在制备雌激素型对器官有选择性而无趋子宫作用的药物中的应用

Publications (2)

Publication Number Publication Date
CN1509712A CN1509712A (zh) 2004-07-07
CN100581541C true CN100581541C (zh) 2010-01-20

Family

ID=7861630

Family Applications (2)

Application Number Title Priority Date Filing Date
CN03145494A Expired - Fee Related CN100581541C (zh) 1998-03-19 1999-03-19 总状花升麻提取物在生产用于抑制黄体生成素活性的雌激素型器官选择性药物中的用途
CNB998041238A Expired - Fee Related CN100444867C (zh) 1998-03-19 1999-03-19 含有鸢尾黄素的射干提取物在制备雌激素型对器官有选择性而无趋子宫作用的药物中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB998041238A Expired - Fee Related CN100444867C (zh) 1998-03-19 1999-03-19 含有鸢尾黄素的射干提取物在制备雌激素型对器官有选择性而无趋子宫作用的药物中的应用

Country Status (20)

Country Link
EP (1) EP1064009B2 (https=)
JP (2) JP2002506827A (https=)
KR (1) KR100623333B1 (https=)
CN (2) CN100581541C (https=)
AT (1) ATE225182T1 (https=)
AU (1) AU755900C (https=)
BR (1) BR9908256A (https=)
CA (1) CA2321444C (https=)
CZ (1) CZ292684B6 (https=)
DE (2) DE19812204A1 (https=)
DK (1) DK1064009T4 (https=)
ES (1) ES2184427T5 (https=)
HU (1) HU227694B1 (https=)
MX (1) MXPA00007986A (https=)
PL (1) PL194096B1 (https=)
PT (1) PT1064009E (https=)
RU (2) RU2228188C2 (https=)
SE (1) SE1064009T4 (https=)
TR (1) TR200002686T2 (https=)
WO (1) WO1999047149A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000302667A (ja) * 1999-04-23 2000-10-31 Kobe Tennenbutsu Kagaku Kk 豊胸促進剤
CA2414247C (en) * 2000-06-29 2012-11-27 Quick-Med Technologies, Inc. Cosmetic composition and method comprising a hydroxamate mmpi and a triterpenoid glycoside
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
DE10054641A1 (de) 2000-11-03 2002-05-16 Schaper & Bruemmer Gmbh Verwendung einer Zubereitung von Cimicifuga racemosa
DE10123503A1 (de) * 2001-05-15 2002-11-21 Bionorica Ag Verwendung von Extrakten und Zubereitungen aus Irisgewächsen und Tectorigenin als organselektives Arzneimittel zur Behandlung von sexualhormon-abhängigen Erkrankungen des Urogenitaltraktes
DE10127897B4 (de) * 2001-06-08 2006-04-20 Bionorica Ag Manteltablette mit Pflanzentrockenextrakten
DE10146159A1 (de) * 2001-09-19 2003-04-10 Bionorica Ag Verwendung von Extrakten aus Cimicifuga-Arten als organselektives Arzneimittel zur Behandlung von sexualhormonabhängigen Erkrankungen des Urogenitaltraktes
EP1325681A1 (en) * 2001-12-11 2003-07-09 Société des Produits Nestlé S.A. Composition for promotion of bone growth and maintenance of bone health
DE10206390A1 (de) * 2002-02-15 2003-08-28 Bionorica Ag Verwendung von selektiv den Estrogenrezeptor beta modulierenden phytoestrogenhaltigen Extrakten
JP4605984B2 (ja) * 2002-12-20 2011-01-05 アサヒビール株式会社 ストレス緩和剤
DE602004020463D1 (de) * 2003-05-15 2009-05-20 Chengdu Dikang Pharmaceutical Isoflavonderivative von tectoridin, deren herstellung und antivirale medikamente, die diese als wirksame bestandteile enthalten
EP1588739A1 (en) * 2004-04-23 2005-10-26 Schaper & Brümmer Gmbh & Co. Kg Composition comprising a combination of calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
EP1591143A1 (en) * 2004-04-26 2005-11-02 Schaper & Brümmer Gmbh & Co. Kg Composition comprising a combination of Calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
US7887851B2 (en) 2004-06-07 2011-02-15 Kao Corporation Aromatase activator
CN100381435C (zh) * 2005-03-24 2008-04-16 深圳海王药业有限公司 射干总黄酮提取物及其制备方法和其在药物制备中的应用
EP1745796A1 (de) 2005-07-19 2007-01-24 Bionorica Research GmbH Kombinationspräparat insbesondere zur Therapie des Prostatakarzinoms
CN101057854B (zh) * 2006-05-31 2010-05-12 南京大学 升麻环菠萝蜜烷型三萜类化合物在抗骨质疏松及更年期综合症的用途
DE102007044916A1 (de) 2007-09-19 2009-04-23 Bionorica Ag Kosmetische oder dermatologische Zusammensetzung zur topischen Verwendung
KR100928013B1 (ko) * 2008-01-25 2009-11-24 이화여자대학교 산학협력단 범부채 추출물을 이용한 돌피의 생장 촉진방법 및 이방법을 적용한 중금속 오염 토양의 정화방법
CN101797265A (zh) * 2010-04-09 2010-08-11 中国人民解放军第二军医大学 射干总异黄酮或异黄酮类化合物在制备防治妇女病的药物或食品中的应用
EP2545932A1 (de) 2011-07-12 2013-01-16 Bionorica Se Ausgewählte Cimicifuga-Fraktionen zur Behandlung von Osteoporose
WO2013007807A1 (de) 2011-07-12 2013-01-17 Bionorica Se Ausgewählte cimicifuga-fraktionen zur behandlung von osteoporose
EP2620155A1 (de) 2012-01-30 2013-07-31 Bionorica SE Arzneimittel enthaltend Cimicifuga zur Anwendung bei der Behandlung von Sarkopenie und Herzmuskelschwäche
CN102525907B (zh) * 2012-02-22 2013-06-05 四川省中医药科学院 鸢尾苷元磺酸钠注射液
CN102631363A (zh) * 2012-04-11 2012-08-15 李超生 鸢尾苷在制备防治骨质疏松症的药物中的应用
KR20150018831A (ko) * 2012-06-22 2015-02-24 골든 바이오테크놀러지 코포레이션 동맥경화성 혈관 질환을 치료하기 위한 방법 및 조성물
AU2013285492B2 (en) 2012-07-03 2015-11-12 Max Zeller Soehne Ag Novel pharmacological use of Cimicifuga extract
JP2014091706A (ja) * 2012-11-02 2014-05-19 Kao Corp Ｇｌｐ−１分泌促進剤
KR101965849B1 (ko) * 2017-03-07 2019-04-04 주식회사 엘지생활건강 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물
KR101964841B1 (ko) * 2017-03-07 2019-08-07 주식회사 엘지생활건강 여성 갱년기 증상 개선용 조성물
TWI761372B (zh) * 2017-09-22 2022-04-21 日商東洋新藥股份有限公司 組合物
WO2020141083A1 (en) 2018-12-31 2020-07-09 Max Zeller Soehne Ag Combination of cimicifuga and petasites extracts for anticancer therapy and prophylaxis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6330417A (ja) * 1986-07-23 1988-02-09 Tsumura Juntendo Inc 抗アレルギ−剤
US5411733A (en) * 1992-04-27 1995-05-02 Hozumi; Toyoharu Antiviral agent containing crude drug
RU2012348C1 (ru) * 1992-10-30 1994-05-15 Анна Геннадиевна Пономарева Сбор лекарственных трав, обладающий общеукрепляющим действием, "нежность", "осень", "наташа"
ES2132855T3 (es) * 1995-09-07 1999-08-16 Oreal Extracto de iridaceas y composiciones que lo contienen.
KR19990067010A (ko) * 1995-10-23 1999-08-16 오스테오스크린, 인코포레이티드 골결핍 상태의 치료용 조성물 및 그 치료방법
JPH09301884A (ja) * 1996-05-15 1997-11-25 Ichimaru Pharcos Co Ltd ヒオウギ抽出物及びα−ヒドロキシ酸を含有するテストステロン５α−リダクターゼ阻害剤とその応用
JPH107580A (ja) * 1996-06-15 1998-01-13 Michio Yoshida コラゲナ−ゼ阻害剤
JP3665848B2 (ja) * 1996-09-18 2005-06-29 木村 幸代 ヒメヒオウギズイセン球根抽出液の発酵飲料及びその製造方法
US5753266A (en) * 1996-12-03 1998-05-19 Youssefyeh; Parvin Safflower seed powder compositions for the treatment of rheumatoid based arthritic diseases
DE19652183C1 (de) * 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Verwendung eines Extraktes aus Cimicifuga racemosa
RU2114629C1 (ru) * 1997-04-10 1998-07-10 Бабаскина Людмила Ивановна Сбор лекарственных трав, обладающий общеукрепляющим и нормализующим гормональный статус в климактерическом периоде действием

Also Published As

Publication number Publication date
SE1064009T4 (sv) 2008-09-23
ES2184427T5 (es) 2008-12-16
EP1064009A1 (de) 2001-01-03
EP1064009B2 (de) 2008-07-30
DK1064009T3 (da) 2002-11-04
HU227694B1 (en) 2011-12-28
RU2228188C2 (ru) 2004-05-10
DE59902932D1 (de) 2002-11-07
CN1509712A (zh) 2004-07-07
KR20010040829A (ko) 2001-05-15
HUP0200921A3 (en) 2004-05-28
JP2002506827A (ja) 2002-03-05
RU2263505C2 (ru) 2005-11-10
MXPA00007986A (es) 2002-08-06
HUP0200921A2 (hu) 2002-12-28
EP1064009B9 (de) 2003-02-05
PL342486A1 (en) 2001-06-04
SE1064009T3 (sv) 2003-01-21
CZ20002810A3 (cs) 2000-12-13
TR200002686T2 (tr) 2000-12-21
DE19812204A1 (de) 1999-11-04
ATE225182T1 (de) 2002-10-15
HK1035660A1 (en) 2001-12-07
WO1999047149A1 (de) 1999-09-23
BR9908256A (pt) 2000-12-12
AU755900B2 (en) 2003-01-02
DK1064009T4 (da) 2008-08-25
RU2003137324A (ru) 2005-06-10
PL194096B1 (pl) 2007-04-30
KR100623333B1 (ko) 2006-12-05
CA2321444A1 (en) 1999-09-23
JP2010132699A (ja) 2010-06-17
CN1293575A (zh) 2001-05-02
EP1064009B1 (de) 2002-10-02
CZ292684B6 (cs) 2003-11-12
ES2184427T3 (es) 2003-04-01
AU3146699A (en) 1999-10-11
CN100444867C (zh) 2008-12-24
SE1064009T5 (sv) 2003-04-15
AU755900C (en) 2005-04-21
PT1064009E (pt) 2003-02-28
CA2321444C (en) 2012-10-02

Similar Documents

Publication Publication Date Title
CN100581541C (zh) 总状花升麻提取物在生产用于抑制黄体生成素活性的雌激素型器官选择性药物中的用途
Yang et al. Licorice ethanol extract improves symptoms of polycytic ovary syndrome in Letrozole-induced female rats
Mendelson et al. Marihuana smoking suppresses luteinizing hormone in women.
EP1474119B1 (de) Verwendung von selektiv den estrogenrezeptor beta modulierenden phytoestrogenhaltigen extrakten
Yang et al. Traditional medicine (Mahuang-Tang) improves ovarian dysfunction and the regulation of steroidogenic genes in letrozole-induced PCOS rats
Takaoka et al. Oestrogen protects against ischaemic acute renal failure in rats by suppressing renal endothelin-1 overproduction
Aswar et al. Estrogenic activity of friedelin rich fraction (IND-HE) separated from Cissus quadrangularis and its effect on female sexual function
EP3403656B1 (en) Composition, containing loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome
CN102266415B (zh) 一种复方中药在防治骨质疏松疾病中的应用
Radenahmad et al. Serum levels of 17β-estradiol in ovariectomized rats fed young-coconut-juice and its effect on wound healing
US20070122503A1 (en) Use of extracts from cimicifuga racemosa and of tectorigenin as an estrogen-type, organoselective medicament having no uterotrophic effect
Welsch et al. Comparative effects of hypophysectomy, ergocornine and ergocornine‐reserpine treatments on rat mammary carcinoma
RS50350B (sr) Upotreba 11beta-(4-acetilfenil)-17beta-hidroksi-17alfa-(1,1,2,2,2-pentafluoretil)estra-4,9-dien-3-ona za pripremanje medikamenta za lečenje kancera dojke, jajnika, endometrijuma, mijeloma i meningioma
Paturkar Influence of butea Monosperma and moringa oleifera leaf extracts on reproductive hormones in male albino rats
HK1035660B (en) Utilization of extracts from iris plants, cimicifuga racemosa and tectorigenin as an estrogen-like organ-selective medicament without uterotropic effects
Seidlová-Wuttke et al. Cimicifuga racemosa: a selective estrogen receptor modulator?
CN115944644A (zh) 一种具有改善卵巢功能减退功效的组合物及其应用
Forcelledo et al. Ovum transport in cyclic rats rendered hypo-oestrogenic by treatment with 4-hydroxy-4-androstene-3, 17-dione

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100120

Termination date: 20140319